
Amicus Therapeutics (NASDAQ: FOLD)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Amicus Therapeutics Returns vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Amicus Therapeutics Company Info
A global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases, including an industry leading rare disease gene therapy portfolio.
News & Analysis
Investors cheered an analyst's upgrade of the biotech stock.
These five biotech stocks could post life-changing gains for early-bird investors.
Amicus Therapeutics, Amarin, and CRISPR Therapeutics are all way oversold.
These companies could crush the broader markets this year.
An analyst upgrade is driving Amicus' stock higher today.
The gene therapy stock is trading at its lowest level in over two years. It recently announced preliminary third-quarter 2019 operating results.
The competitive outlook for a key therapy is worrying investors.
Investor concerns over the competitive outlook for the company's Pompe disease therapy candidate weighed on its stock price.
Valuation
Earnings Transcripts
FOLD earnings call for the period ending September 30, 2021.
FOLD earnings call for the period ending June 30, 2021.
FOLD earnings call for the period ending March 31, 2021.
FOLD earnings call for the period ending March 31, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.